Galderma, the world’s largest independent dermatology company, announced that it has signed a definitive agreement to acquire ALASTIN Skincare, Inc., a specialty aesthetics company dedicated to developing innovative and clinically tested physician-dispensed skin care products. The acquisition is subject to customary closing conditions and necessary regulatory approvals. Financial terms of the transaction have not been disclosed.
ALASTIN’s premium skincare portfolio is fully incremental to and synergistic with Galderma’s integrated dermatology platform. Founded in 2015, ALASTIN provides a comprehensive collection of cutting-edge, scientifically proven products for daily skin care regimens and peri-procedural use. ALASTIN’s product offerings are backed by its patented TriHex Technology, a proprietary blend of peptides and active botanicals to support the appearance of rejuvenated skin. Since inception, ALASTIN has delivered rapid and consistent sales growth, achieving a CAGR of 106% between 2016 and 2020, one of the highest of any professional skin care company. ALASTIN Skincare was ranked the most preferred skin care brand in a blinded survey of physicians who carry ALASTIN and other skin care brands, conducted by Corsica Life Sciences in December 2020. The company was named as one of Forbes' best startup employers in America in 2020 and 2021 and was named as one of the fastest growing private companies in America on the INC 5000 2020 and 2021 lists.
Read more at Business Wire >>